ISA PHARMACEUTICALS (IDFF)

Projektträger – zwischengeschaltetes Finanzinstitut

ISA PHARMACEUTICALS BV

Ort

• Niederlande

Beschreibung

The project supports the company's research and development investments to complete the late stage development (clinical, regulatory, and manufacturing) of ISA101b - a synthetic long peptide (SLP) targeting human papilloma viruses (HPV) - in two HPV-induced therapeutic areas i.e. cervical, head and neck cancer.

Ziele

The proceeds from the EIB loan will be used to co-finance the project, which - if successful - will create new treatment options for patients suffering from these diseases, thereby addressing a substantial unmet medical need, and saving and improving the lives of thousands of patients. The project will also contribute to the growth of a European biopharmaceutical company and the creation of new high-skilled jobs.

Sektor(en)

• Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 20 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 48 million

Umweltaspekte

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details verified during the appraisal are aligned with best practices.

Auftragsvergabe

The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions.

Projektstatus

Unterzeichnet - 28/06/2019